Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21209
Abstract: e21209Background: Ram+docetaxel & ICIs are FDA-approved for aNSCLC pts failing Pt therapy. Optimal sequencing of these regimens is unknown. The study objective was to evaluate sequence patterns and... read more here.
Keywords: immune checkpoint; checkpoint inhibitors; ram immune; sequencing ramucirumab ... See more keywords